Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313220551> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W4313220551 endingPage "158" @default.
- W4313220551 startingPage "158" @default.
- W4313220551 abstract "Introduction: OctaplasLG (Octapharma AG, Switzerland) is a solvent/detergent (S/D)-treated plasma preparation made from pooled fresh frozen plasma (FFP). First used in 1989 as an FFP alternative, S/D plasma was developed to increase pathogen safety in treating acquired coagulation factor deficiencies during active bleeding, bleeding prevention, and therapeutic plasma exchange (TPE). Here, we review published literature on the efficacy, safety, and cost effectiveness of S/D plasma. Methods: Medline (PubMed) and Google Scholar were searched for articles reporting “octaplas” or “octaplasLG” efficacy and/or safety in clinical settings. Results: Efficacy/safety was shown for multiple indications in different patient groups, such as cardiac surgery (n=125/117 adult/pediatric patients receiving S/D plasma), liver disease (n=30/20), liver transplantation (n=269/5), hemodilution/blood loss (n=47 adults), obstetrics/gynecology (n=38 adults), and TPE (n=167/41), as well as in 162 critically ill neonates/pediatric patients. Studies demonstrated S/D plasma could improve standard coagulation markers comparable with FFP and was also associated with greater endothelial protection. S/D plasma had lower incidences of allergic and febrile non-hemolytic transfusion reactions, and transfusion-associated circulatory overload compared with FFP, and almost no confirmed cases of transfusion-related acute lung injury reported after >13 million units transfused. Studies suggested S/D plasma was more cost-effective than FFP due to lower risk of transfusion-related complications. Literature results showed some countries have replaced FFP with S/D plasma to improve plasma safety. A new freeze-dried form has been recently developed with similar biochemical quality to S/D plasma, and is of particular interest for pre-hospital settings, e.g., trauma, where rapid reconstitution/flexible storage improves logistics/utilization. Conclusions: Available evidence from 30 years of global use indicates that S/D plasma is an efficacious alternative to FFP in adult/pediatric patients for multiple indications, with a favorable safety profile. The clinical utility of S/D plasma is also expanding, with the freeze-dried form having the potential to further improve patient outcomes and reduce costs." @default.
- W4313220551 created "2023-01-06" @default.
- W4313220551 creator A5047726532 @default.
- W4313220551 creator A5050931066 @default.
- W4313220551 creator A5055812879 @default.
- W4313220551 date "2022-12-15" @default.
- W4313220551 modified "2023-10-17" @default.
- W4313220551 title "344: THIRTY YEARS OF SOLVENT/DETERGENT-TREATED PLASMA FOR TRANSFUSION IN CRITICALLY ILL PATIENTS" @default.
- W4313220551 doi "https://doi.org/10.1097/01.ccm.0000907104.62982.89" @default.
- W4313220551 hasPublicationYear "2022" @default.
- W4313220551 type Work @default.
- W4313220551 citedByCount "0" @default.
- W4313220551 crossrefType "journal-article" @default.
- W4313220551 hasAuthorship W4313220551A5047726532 @default.
- W4313220551 hasAuthorship W4313220551A5050931066 @default.
- W4313220551 hasAuthorship W4313220551A5055812879 @default.
- W4313220551 hasBestOaLocation W43132205511 @default.
- W4313220551 hasConcept C126322002 @default.
- W4313220551 hasConcept C141071460 @default.
- W4313220551 hasConcept C177713679 @default.
- W4313220551 hasConcept C2776468924 @default.
- W4313220551 hasConcept C2777259802 @default.
- W4313220551 hasConcept C2777714996 @default.
- W4313220551 hasConcept C66112548 @default.
- W4313220551 hasConcept C71924100 @default.
- W4313220551 hasConcept C89560881 @default.
- W4313220551 hasConceptScore W4313220551C126322002 @default.
- W4313220551 hasConceptScore W4313220551C141071460 @default.
- W4313220551 hasConceptScore W4313220551C177713679 @default.
- W4313220551 hasConceptScore W4313220551C2776468924 @default.
- W4313220551 hasConceptScore W4313220551C2777259802 @default.
- W4313220551 hasConceptScore W4313220551C2777714996 @default.
- W4313220551 hasConceptScore W4313220551C66112548 @default.
- W4313220551 hasConceptScore W4313220551C71924100 @default.
- W4313220551 hasConceptScore W4313220551C89560881 @default.
- W4313220551 hasIssue "1" @default.
- W4313220551 hasLocation W43132205511 @default.
- W4313220551 hasLocation W43132205512 @default.
- W4313220551 hasOpenAccess W4313220551 @default.
- W4313220551 hasPrimaryLocation W43132205511 @default.
- W4313220551 hasRelatedWork W2002120878 @default.
- W4313220551 hasRelatedWork W2003938723 @default.
- W4313220551 hasRelatedWork W2047967234 @default.
- W4313220551 hasRelatedWork W2118496982 @default.
- W4313220551 hasRelatedWork W2206874960 @default.
- W4313220551 hasRelatedWork W2412481443 @default.
- W4313220551 hasRelatedWork W2423660131 @default.
- W4313220551 hasRelatedWork W2439875401 @default.
- W4313220551 hasRelatedWork W3030285381 @default.
- W4313220551 hasRelatedWork W2493990840 @default.
- W4313220551 hasVolume "51" @default.
- W4313220551 isParatext "false" @default.
- W4313220551 isRetracted "false" @default.
- W4313220551 workType "article" @default.